Patient education • High-risk pregnancy

Hemolytic Disease of the Fetus and Newborn

A clear guide for families navigating an at-risk pregnancy

OpenMFM patient educationUse ← → keys
Orientation

Our goal

Understand your risk, your baby’s monitoring, and how specialists prevent or treat anemia before and after birth.

Definition

What is HDFN?

Maternal antibodies can cross the placenta and remove fetal red blood cells. This may cause anemia before birth and jaundice after birth.

Cause

How antibodies form

Exposure to unfamiliar red-cell antigens may occur during pregnancy, birth, bleeding, procedures, or transfusion. Your immune system can remember that antigen.

Interpretation

A positive screen is a starting point

A positive antibody screen does not mean your baby is anemic. The next steps identify the antibody and whether your baby carries its target antigen.

Risk

Some antibodies need closer attention

Anti-D, anti-c, and anti-Kell can cause important fetal or newborn disease. Many other antibodies cause little or no fetal harm.

Screening

Screening finds the signal

Early prenatal testing checks your blood type and red-cell antibodies. If positive, the laboratory identifies the antibody and measures its level.

Diagnosis of susceptibility

Is your baby susceptible?

Targeted cell-free fetal DNA may identify your baby’s red-cell antigen after 10 weeks. If the antigen is absent, that antibody cannot attack fetal cells.

Risk interpretation

History and titers guide monitoring

Prior affected pregnancies increase risk. Rising or critical titers prompt fetal surveillance. Thresholds vary by antibody and laboratory; anti-Kell is managed differently.

Fetal surveillance

MCA Doppler: a painless screening test

Ultrasound measures blood speed in a fetal brain artery. Faster flow can signal anemia. The test does not expose your baby to radiation.

Interpretation

Interpreting the Doppler

1.5 MoM

Below 1.5 MoM is generally reassuring. At or above 1.5 MoM raises concern for moderate-to-severe anemia and requires specialist evaluation.

Clinical algorithm

The clinical pathway

Screen
Identify antibody
Determine fetal antigen
Review history and titers
MCA Doppler
Fetal therapy
Planned delivery
Clinical action

When anemia is suspected

Your care team may recommend fetal blood sampling at a fetal therapy center. The same procedure can confirm anemia and immediately deliver compatible blood.

Fetal treatment

Intrauterine transfusion

Ultrasound guides a needle into the umbilical vein. Compatible red cells treat fetal anemia. Some babies need repeat transfusions before planned delivery.

Team-based care

Your high-risk care team

Maternal-fetal medicine, fetal therapy, transfusion medicine, obstetrics, and neonatology coordinate surveillance, blood availability, delivery timing, and newborn care.

Delivery planning

Delivery is planned, not automatic

Many stable pregnancies reach early term. Earlier delivery may be safer if anemia worsens, monitoring changes, transfusion is unsuitable, or another obstetric concern develops.

After birth

Your baby’s first checks

After birth, clinicians assess breathing, color, blood type, antibodies, hemoglobin, and bilirubin. Results determine nursery care, NICU observation, and treatment.

Newborn treatment

Treatments are tailored

Phototherapy treats jaundice. Transfusion treats anemia. Exchange transfusion is reserved for dangerous bilirubin levels. IVIG has selective use when bilirubin rises despite intensive phototherapy.

Newborn follow-up

Follow-up still matters

Prevention

Rh immune globulin prevents anti-D

Rh immune globulin helps unsensitized RhD-negative patients avoid anti-D antibodies. It does not remove existing anti-D or prevent antibodies against other antigens.

Practical actions

What you can do

Keep appointments. Share prior pregnancy and transfusion records. Ask which antibody you have, whether your baby is susceptible, and what changes require urgent contact.

Counseling

Reasons for confidence

Most at-risk pregnancies are identified before severe illness. Surveillance can detect anemia early, and specialized fetal and newborn treatments are available when needed.

Shared decisions

Ask your care team

Which antibody?
Is baby antigen-positive?
When does monitoring begin?
Where will I deliver?
What follow-up is planned?
Educational disclaimer

Use this guide with your care team

This presentation provides general education and does not replace medical advice, diagnosis, or treatment from your own clinicians. Your antibody, pregnancy history, laboratory results, ultrasound findings, and local resources determine your individual plan.

OpenMFM patient educationSeek urgent care for symptoms your team has told you to watch for
Linked references

Professional guidance

Guidance links open separately1 of 2
Linked references

Updated evidence + patient resources

Partnership

You are not facing this alone

Monitoring creates time to act. Your team will tailor every decision to you and your baby.

← OpenMFM Library